Brain Atrophy in Natalizumab ‐treated Patients with Multiple Sclerosis: A 5‐year Retrospective Study

CONCLUSIONOur results contribute to the increasing knowledge of PBVCs in natalizumab ‐treated MS patients. Our data suggests that after a significant PBVC decrease in the first year, brain atrophy rates show a slowdown during long‐term follow‐up.
Source: Journal of Neuroimaging - Category: Radiology Authors: Tags: Short Communication Source Type: research